India's Sun Pharma buys troubled rival Ranbaxy for $3.2 bn (Update)

April 7, 2014

India's third-biggest drugs company Sun Pharma announced Monday a $3.2-billion deal to buy larger domestic rival Ranbaxy from Daiichi Sankyo, ending the Japanese company's costly run as owner.

Despite Ranbaxy's huge US safety regulatory problems, Sun Pharmaceutical Industries said the transaction offered "tremendous growth opportunities" thanks to Ranbaxy's "significant presence" in the US market as well as in India and other high-growth emerging markets.

"Sun Pharma and Ranbaxy will have a diverse, highly complementary portfolio of specialty and generic products," Sun Pharma managing director Dilip Shanghvi, who founded the company in 1983, said.

But the immediate winner from the deal, analysts said, was Daiichi which extricates itself from its troubled ownership of Ranbaxy while striking a strategic partnership with Sun Pharma.

Daiichi Sankyo's shares were up 3.3 percent at 1,813 yen in Monday's trade.

Daiichi bought New Delhi-based Ranbaxy, India's biggest drug firm by sales, in 2008 for $4.6 billion, believing its dominance in cheap generic medicines would boost the Japanese firm's revenues.

But the Indian company created a huge drain on Daiichi's finances after US regulators slapped import bans on Ranbaxy drugs over quality concerns, and a year after its purchase, the Japanese company announced a $3.84-billion loss on the deal.

"There's no doubt the biggest beneficiary of this (latest) deal is Daiichi," Surya Patra, pharmaceutical analyst at Mumbai's PhillipCapital, told AFP.

The Japanese company will hold about 9.0 percent of the new firm and have a right to nominate one director to Sun Pharma's board under the deal, which involves purchase of $3.2-billion in Ranbaxy shares and the assumption of $800 million in debt which Sun said made the total transaction worth $4 billion.

The agreement would create India's largest drugs manufacturer and the fifth-biggest worldwide by sales while Ranbaxy shareholders will get a nearly 20 percent premium to the average 30-day share price.

Daiichi's President Joji Nakayama acknowledged that his company came out a loser financially, but added that "we've learnt a lot of things and got lots of ideas".

"Today, we have a partnership with a world-leading generic pharmaceutical firm," he told reporters in Tokyo.

"And we're aiming to achieve a great result that will overwhelm our past investment."

US safety concerns

India, known as "pharmacy to the world" because of its vast generics market, supplies medicines to more than 200 countries and is the second-largest US drugs supplier after Canada.

Ranbaxy's shares were down nearly five percent at 437.65 rupees in afternoon trade. Sun Pharma stock was up 1.36 percent at 479.65 rupees as the company said the deal would give it access to Ranbaxy's pipeline of generic drugs and vast Indian rural distribution network.

Sun, based in financial hub Mumbai, said it expected the deal to close by the end of 2014, pending regulatory approvals.

The purchase comes just months after the US Food and Drug Administration (FDA) slapped an import ban on Ranbaxy's fourth plant in India for failing to meet "good manufacturing practices" after bans on the other three.

Sun Pharma, some of whose products the FDA also banned last month over safety concerns, said it intended to work hard to get the banned Ranbaxy facilities re-certified as safe.

"The first focus will be on compliance," managing director Shanghvi told analysts in a conference call, referring to the FDA quality demands.

Ranbaxy last year pleaded guilty in the United States to charges of making adulterated drugs and agreed to a record $500-million settlement, after a whistle-blowing employee revealed a "complicated trail of falsified records and dangerous manufacturing practices".

Aditya Khemka, pharmaceutical analyst at Ambit Capital in Mumbai, said the deal looked attractive despite Ranbaxy's regulatory troubles.

"We need to now see what savings and incremental revenues Sun Pharma can generate from Ranbaxy," he said. Sun said the acquisition was expected to add to its cash earnings per share in the first full year.

Ranbaxy's net loss narrowed to 1.59 billion rupees ($25.6 million) for the quarter ended December 2013 from a 4.92-billion-rupee loss a year earlier, thanks to rising sales in key markets and currency gains.

The combined entity will have operations in 65 countries, 47 manufacturing facilities across five continents and annual revenues of $4.2 billion.

Explore further: Indian drug giant Ranbaxy trims losses but future is bleaker

Related Stories

Indian drug giant Ranbaxy trims losses but future is bleaker

February 5, 2014
Ranbaxy Laboratories, India's biggest generic drugmaker by sales, reported a narrower quarterly loss on Wednesday thanks to rising sales in key markets and currency gains.

India's drugmaker Ranbaxy swings into quarterly net loss

October 29, 2013
India's biggest generic drugmaker Ranbaxy Laboratories swung into a net loss in the third quarter ended September from a profit a year earlier, owing to a weak rupee and foreign exchange losses.

Shares of India's Ranbaxy slide 19% on new US FDA ban

January 24, 2014
Shares in one of India's biggest drugmakers, Ranbaxy Laboratories, slid 19 percent Friday after the US Food and Drug Administration suspended imports from a fourth manufacturing plant of the firm.

Ranbaxy taking 'stringent steps' to end US FDA ban

September 21, 2013
India's biggest drugmaker by sales, Ranbaxy Laboratories, has assured shareholders it is taking "stringent steps" to resolve a US ban on imports of medicines made at its newly renovated showcase plant.

US health watchdog curbs exports from India's Wockhardt

November 27, 2013
The US health regulator has restricted exports from a plant owned by Indian generic drugmaker Wockhardt in the latest ban on its products, sending the company's shares tumbling 14 percent on Wednesday.

Indian drugmaker Ranbaxy faces new US regulation woes (Update 2)

September 16, 2013
Shares in Indian generic drugs giant Ranbaxy Laboratories crashed by as much as 35 percent on Monday after the US Food and Drug Administration suspended imports from one of its factories.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.